Grounded in Expertise
Driven by Experience
Proven Value
Since 2006, we have helped life sciences businesses achieve their full potential.
Since 2006, we have helped life sciences businesses achieve their full potential.
BroadOak Capital Partners is a life sciences focused, boutique financial institution that provides direct investment through BroadOak Asset Management, and investment banking services through BroadOak Partners, to companies in the life sciences tools, diagnostics, and biopharma services sectors. BroadOak has made investments in more than 70 companies and advised on over 50 successful M&A transactions.
Services to help management teams optimize sale processes, mergers, acquisitions, and financing.
15+
120+
7
35
BroadOak advises and invests in life sciences tools, diagnostics, and services companies. Each sector is highly specialized, and most traditional financial institutions do not have the experience or expertise necessary to provide a true partnership. BroadOak is different. Our in-house expertise, access to proprietary information via deep relationships and networks, and reputation built on 15 years of experience give our portfolio companies and clients results that exceed expectations.
Instruments and consumables used in therapeutic discovery and development
Diagnostic tests, test components, and instruments for analysis
Research, development, and manufacturing services for biopharma companies
BroadOak Capital Partners is pleased to share that Halo Labs has been acquired by Waters Corporation. BroadOak has
BroadOak Capital Partners is pleased to share that Rubicon Founders has invested in Horizon Infusions. BroadOak has supported
BroadOak Capital Partners advised Omixon on its sale of the company to Werfen. Omixon, a privately held company
Stay connected
Partner with BroadOak